Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
News and updates for Enanta Pharmaceuticals, Inc. (ENTA) focus on its progress as a clinical-stage biotechnology company developing small molecule drugs for viral infections and immunological diseases. Company press releases frequently highlight clinical data, regulatory designations, pipeline milestones, financial results, capital raises, and intellectual property developments.
Investors following ENTA news can expect detailed coverage of RSV clinical programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an oral L-protein inhibitor. Enanta regularly reports Phase 2 and Phase 2b trial readouts in high-risk adult and pediatric RSV populations, human viral challenge data, and analyses of symptom resolution, viral load reductions, and safety outcomes. Updates also cover Phase 3-enabling activities and interactions with the U.S. Food and Drug Administration on trial design and registration pathways.
News items also track Enanta’s immunology pipeline, such as the nomination of EPS-3903, an oral STAT6 inhibitor for atopic dermatitis and other type 2 immune-driven diseases, and the selection of EDP-978, an oral KIT inhibitor for chronic spontaneous urticaria and other mast cell–driven conditions. Announcements describe preclinical potency, selectivity, and planned IND filings and early clinical timelines, as well as the expansion of discovery programs targeting MRGPRX2.
On the corporate side, ENTA news includes quarterly and annual financial results, commentary on royalty revenue from AbbVie’s HCV regimen MAVYRET/MAVIRET, and disclosures about cash runway expectations. Coverage also includes public equity offerings, underwritten offering terms, and use of proceeds, along with patent litigation developments, such as Enanta’s infringement action in the Unified Patent Court related to its coronavirus protease inhibitor patent. For ongoing insight into ENTA’s clinical, financial, and legal developments, this news feed aggregates the company’s latest official announcements.
Enanta Pharmaceuticals has initiated a Phase 1 clinical trial for EDP-235, a novel coronavirus 3CL protease inhibitor aimed at treating COVID-19. This milestone is crucial as SARS-CoV-2 continues to pose a global health threat, with EDP-235 designed for once-daily oral administration. The trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers. Promising preclinical data indicate EDP-235's potent antiviral activity, with an exceptional EC90 of 33 nanomolar, positioning it as a potential best-in-class treatment. Initial results are expected in Q2 2022, with further developments planned for later in the year.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that CEO Jay R. Luly, Ph.D., will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 3:00 p.m. ET. The event will be accessible via a live webcast on Enanta's website, with a replay available for 90 days. Enanta is focused on developing small molecule drugs targeting viral infections and liver diseases, with key research in areas such as RSV, COVID-19, and HBV, supported by royalties from HCV products developed with AbbVie.
Enanta Pharmaceuticals reported fiscal Q1 2021 revenues of $27.6 million, primarily from royalty revenue linked to AbbVie’s MAVYRET. R&D expenses surged to $48.5 million, reflecting increased clinical study support. The net loss widened to $30.1 million, or $1.48 per share. The company has completed enrollment in its Phase 2b study of EDP-938 for RSV, with topline data expected in Q2 2022. Additionally, they are set to begin a Phase 1 trial for EDP-235, an oral treatment for COVID-19, this month.
Enanta Pharmaceuticals (NASDAQ: ENTA) will report its fiscal Q1 results for the period ending December 31, 2021, on February 8, 2022, post-market. The company will hold a conference call at 4:30 p.m. ET to discuss these results and its R&D pipeline. Enanta focuses on developing small molecule drugs targeting viral infections and liver diseases. Its R&D is supported by royalties from its collaboration with AbbVie on hepatitis C products, notably Glecaprevir, which is marketed as MAVYRET® and MAVIRET®.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced key developments for 2022 during the J.P. Morgan Healthcare Conference on January 11. The company plans to initiate a Phase 1 study of EDP-235, a COVID-19 treatment, in February 2022. Additionally, enrollment is complete for the Phase 2 RSVP study of EDP-938 for RSV, with data expected in Q2 2022. Enanta also introduced EDP-323, a new RSV candidate, aiming for a Phase 1 study in H2 2022. The company remains focused on advancing its virology pipeline and addressing urgent healthcare needs amid ongoing challenges from emerging COVID-19 variants.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that CEO Jay R. Luly, Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:00 p.m. ET. A live webcast will be available on Enanta's website under the 'Events and Presentations' section, with a replay accessible for 30 days post-event.
Enanta focuses on developing small molecule drugs for viral infections and liver diseases, including clinical candidates for RSV, HBV, and COVID-19. Their R&D is funded by royalties from HCV products developed with AbbVie, including the notable drug MAVYRET®.
Enanta Pharmaceuticals has presented first preclinical data for EDP-235, an oral protease inhibitor targeting COVID-19, and reported positive Phase 1b results for EDP-514 in chronic HBV patients. The company terminated the development of EDP-721 due to safety concerns. For the fiscal year ended September 30, 2021, total revenue was $97.1 million, down from $122.5 million in 2020, primarily from unchanged royalty revenue of $23.6 million. Enanta recorded a net loss of $79.0 million for the year. The company expects sufficient cash to meet operational needs for at least two years.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced participation in two virtual investor conferences in December 2021. Jay R. Luly, President and CEO, will speak at the Evercore ISI HealthCONx Conference on December 1, 2021, at 10:30 a.m. ET, and will also present at the Piper Sandler Healthcare Conference on December 2, 2021. A pre-recorded chat will be available to attendees on November 29, 2021. Webcasts will be accessible on Enanta's website and archived for 14 days.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced the discontinuation of EDP-721, an oral HBV RNA destabilizer, due to safety concerns raised in a Phase 1 study. Despite a promising preclinical safety profile, emerging safety signals prompted the decision to prioritize patient safety. The company remains focused on EDP-514, a core inhibitor for HBV, which has shown robust antiviral activity in earlier trials. Enanta aims to develop a functional cure for chronic hepatitis B, leveraging its drug discovery capabilities and ongoing research efforts.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) will release its fiscal fourth-quarter and full-year financial results on November 22, 2021, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results and updates on their R&D pipeline, which includes candidates for RSV, HBV, and COVID-19. The company continues to fund its R&D through royalties from its collaboration with AbbVie on HCV products, specifically the protease inhibitor Glecaprevir.